Submit your email to push it up the queue
Cardiovascular Systems, Inc. (CSI) is a leading medical device company headquartered in the United States, specialising in innovative solutions for the treatment of cardiovascular disease. Founded in 1989, CSI has made significant strides in the industry, particularly with its advanced technologies designed to improve patient outcomes in peripheral and coronary artery disease. The company is renowned for its unique orbital atherectomy systems, which effectively remove plaque from arteries, enhancing blood flow and reducing the need for more invasive procedures. With a strong presence in major operational regions across North America and Europe, CSI has established itself as a key player in the cardiovascular sector. Notable achievements include numerous FDA approvals and a commitment to ongoing research and development, solidifying its market position as a trusted provider of cutting-edge cardiovascular solutions.
How does Cardiovascular Systems, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Cardiovascular Systems, Inc.'s score of 54 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cardiovascular Systems, Inc., headquartered in the US, currently does not report specific carbon emissions data, as no emissions figures are available. However, the company is part of a corporate family that includes Abbott Laboratories, from which it inherits climate commitments and initiatives. Abbott Laboratories has established science-based targets for emissions reductions, which are cascaded down to Cardiovascular Systems, Inc. This includes commitments to reduce Scope 1 and Scope 2 emissions, as well as engaging in efforts to address Scope 3 emissions through supply chain management and product lifecycle assessments. While specific reduction targets for Cardiovascular Systems, Inc. are not detailed, the overarching goals set by Abbott Laboratories reflect a commitment to sustainability and climate action. As a current subsidiary of Abbott Laboratories, Cardiovascular Systems, Inc. aligns with industry standards and practices aimed at mitigating climate impact, although specific initiatives or targets for the subsidiary are not explicitly outlined. The company is expected to contribute to the broader climate goals set by its parent organisation, reinforcing its commitment to reducing carbon emissions and promoting environmental responsibility.
Access structured emissions data, company-specific emission factors, and source documents
2010 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 578,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 691,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | - | - | - | - | - | - | - | - | - | 00,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cardiovascular Systems, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.